Capecitabine for the Oral Treatment of Metastatic Breast Cancer
Open Access
- 1 November 2006
- journal article
- Published by SAGE Publications in Women's Health
- Vol. 2 (6) , 805-817
Abstract
Women with metastatic breast cancer require tailored chemotherapy that improves outcomes without compromising quality of life. Capecitabine, a pro-drug of 5-fluorouracil, is an oral fluoropyrimidine carbamate that is sequentially activated in a three-step process. This results in the preferential production of 5-fluorouracil in tumors rather than in normal surrounding tissue, improving the tolerability and efficacy of 5-fluorouracil. In combination with docetaxel, capecitabine is the first agent that has shown superior activity to single-agent docetaxel, and it is a particularly appropriate option for younger, fitter patients with rapidly progressing disease and/or visceral metastases. However, for older patients and those with comorbidities and/or after progression to taxanes, single-agent capecitabine may be the best option. Its role in earlier disease stages (adjuvant therapy) is being investigated.Keywords
This publication has 59 references indexed in Scilit:
- Localization of thymidine phosphorylase in breast cancer tissueMedical Molecular Morphology, 2005
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorinEuropean Journal of Cancer, 2002
- A Systematic Overview of Chemotherapy Effects in Breast CancerActa Oncologica, 2001
- Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5?-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsInternational Journal of Cancer, 1999
- A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drugInvestigational New Drugs, 1999
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEuropean Journal of Cancer, 1998
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Angiogenic activity of enzymesNature, 1994
- A study of quality of life in cancer patients receiving palliative chemotherapySocial Science & Medicine, 1992